论文部分内容阅读
目的 探讨p16和c erbB 2蛋白表达与乳癌临床病理因素及预后的关系。方法 采用免疫组化和PCR SSCP技术 ,分别检测 5 0例乳癌p16 ,c erbB 2蛋白的表达和 2 0例乳癌p16基因的纯合性缺失及突变。结果 5 0例乳癌中 ,17例 (34 0 % )p16蛋白表达阳性 ,2 4例 (4 8 0 % )c erbB 2蛋白表达阳性。 2 0例乳癌中无p16基因的纯合性缺失 ,1例p16基因外显子 2有点突变。结果表明 ,p16蛋白表达与乳癌的临床病理因素及预后无明显相关性。c erbB 2蛋白表达在有淋巴结转移的乳癌中较多见 (P =0 .0 2 37) ,c erbB 2蛋白表达阳性组 5年生存率较低 (P =0 .0 16 9)。p16和c erbB 2蛋白表达之间不存在一致性关系。p16和c erbB 2蛋白表达均不是影响乳癌患者预后的独立因素。结论 c erbB 2蛋白表达阳性的乳癌患者淋巴结转移率较高 ,远期生存率较低。p16基因在乳腺癌中的突变率较低 ,它的发生可能是乳腺癌发展较晚期的表现
Objective To investigate the relationship between the expression of p16 and c erbB 2 and the clinicopathological features and prognosis of breast cancer. Methods Immunohistochemistry and PCR SSCP were used to detect the expression of p16 and c erbB 2 protein in 50 cases of breast cancer and the homozygous deletion and mutation of p16 gene in 20 cases of breast cancer. Results Among the 50 cases of breast cancer, 17 cases (34 0%) had positive p16 protein and 24 cases (4800%) had positive c erbB 2 protein. 20 cases of breast cancer without p16 gene homozygous deletion, a case of p16 gene exon 2 a little mutation. The results showed that, p16 protein expression and clinicopathological factors and prognosis of breast cancer no significant correlation. The expression of c erbB 2 protein was more common in patients with lymph node metastasis (P = 0.0273). The 5-year survival rate of patients with positive c erbB 2 protein expression was lower (P = 0.016 9). There is no consistent relationship between p16 and c erbB 2 protein expression. Neither p16 nor c erbB 2 protein expression was an independent factor affecting the prognosis of patients with breast cancer. Conclusion The breast cancer patients with positive c erbB 2 protein have higher lymph node metastasis rate and lower long-term survival rate. The mutation rate of p16 gene in breast cancer is low, which may be the result of the later development of breast cancer